z-logo
Premium
Structure of a novel phosphotyrosine‐binding domain in Hakai that targets E‐cadherin
Author(s) -
Mukherjee Manjeet,
Chow Soah Yee,
Yusoff Permeen,
Seetharaman J,
Ng Cherlyn,
Sinniah Saravanan,
Koh Xiao Woon,
Asgar Nur Farehan M,
Li Dan,
Yim Daniel,
Jackson Rebecca A,
Yew Jingxi,
Qian Jingru,
Iyu Audrey,
Lim Yoon Pin,
Zhou Xingding,
Sze Siu Kwan,
Guy Graeme R,
Sivaraman J
Publication year - 2012
Publication title -
the embo journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.484
H-Index - 392
eISSN - 1460-2075
pISSN - 0261-4189
DOI - 10.1038/emboj.2011.496
Subject(s) - biology , plasma protein binding , microbiology and biotechnology , cadherin , computational biology , genetics , cell
Phosphotyrosine‐binding domains, typified by the SH2 ( S rc h omology 2) and PTB domains, are critical upstream components of signal transduction pathways. The E3 ubiquitin ligase Hakai targets tyrosine‐phosphorylated E‐cadherin via an uncharacterized domain. In this study, the crystal structure of Hakai (amino acids 106–206) revealed that it forms an atypical, zinc‐coordinated homodimer by utilizing residues from the phosphotyrosine‐binding domain of two Hakai monomers. Hakai dimerization allows the formation of a phosphotyrosine‐binding pocket that recognizes specific phosphorylated tyrosines and flanking acidic amino acids of Src substrates, such as E‐cadherin, cortactin and DOK1. NMR and mutational analysis identified the Hakai residues required for target binding within the binding pocket, now named the HYB domain. ZNF645 also possesses a HYB domain but demonstrates different target specificities. The HYB domain is structurally different from other phosphotyrosine‐binding domains and is a potential drug target due to its novel structural features.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom